Topic: How To Invest

Hi Pat. Could I get your view on Warner Chilcott? Thanks.

Article Excerpt

Warner Chilcott plc, $25.91, symbol WCRX on Nasdaq (Shares outstanding: 251.5 million; Market cap: $6.5 billion), researches and develops drugs. Its main products include Femcom Fe and Loestrin24 Fe (birth control), Enablex (bladder control), Actonel (osteoporosis), Doryx (acne) and Asacol (colitis). Warner Chilcott is based in Bermuda, but its main plants are in the U.S., Puerto Rico, Northern Ireland and Germany. It mainly sells its products in North America and Europe. In the three months ended September 30, 2009, the company earned $424.2 million, or $1.69 a share. However, that included a $393.1million gain on the sale of its exclusive U.S. marketing rights to two psoriasis drugs: Taclonex and Dovonex. Warner Chilcott sold these rights to LEO Pharma A/S, which originally developed these drugs, for $1 billion. Without this item, Warner Chilcott would have earned $103.2 million, or $0.41 a share, in the quarter. That’s a gain of 157.4% from $40.1 million, or $0.16 a share, a year earlier. Revenue rose…